XML 49 R24.htm IDEA: XBRL DOCUMENT v3.25.4
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company operates as one operating segment focused on developing and commercializing innovative therapeutics primarily in the U.S. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies.
The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the chief executive officer, who is the Company's CODM, in assessing segment performance and deciding how to allocate resources on a consolidated basis.
The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using income (loss) from operations. Net income (loss) is also a measure that is considered in monitoring budget versus actual results. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents information about reported segment revenues, segment profit and significant segment expenses for the years ended December 31, 2025, 2024 and 2023:
 Years Ended December 31,
 202520242023
Revenues$236,196 $160,180 $194,623 
Less:
Direct cost of product and other revenue28,136 15,970 26,525 
Panion royalty11,326 9,097 10,048 
Excess firm purchase commitment charge— 2,068 1,533 
Amortization of intangible asset— 36,042 36,042 
Research and development62,359 37,652 63,079 
Selling, general and administrative107,480 106,545 100,233 
License3,396 3,220 3,237 
Restructuring— 58 181 
Income (loss) from operations23,499 (50,472)(46,256)
Other income (expense)
Interest expense(24,179)(18,185)(6,032)
Other income58 94 887 
Change in fair value of warrant liability(3,099)(330)— 
Loss on extinguishment of debt— (517)— 
Loss on termination of lease— — (524)
Net loss before income taxes(3,721)(69,410)(51,925)
Income tax expense(1,624)— — 
Net loss$(5,345)$(69,410)$(51,925)